The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the accelerating pace of innovation in the biotechnology sector, Thermo Fisher Scientific has been selected as a partner for Arcturus Therapeutics. Under this collaboration, Thermo Fisher will handle the development and manufacturing of an investigational mRNA-based therapy. According to reports, the partnership aims to leverage Thermo Fisher's massive production capabilities to support Arcturus' pipeline in messenger RNA therapeutics.
This partnership comes at a time when the healthcare sector faces mixed pressures, with markets closely monitoring challenges related to academic funding and geopolitical pressures linked to the Chinese market. Looking at peer performance, market data shows relative stability in shares of major firms like Danaher and Agilent Technologies, which compete in the bioprocessing services space. Per market data, lab service providers are seeking to diversify their portfolios to reduce reliance on slowing traditional markets.
TMO stock stood at $523.44 at the close of July 02, 2026, after reaching an intraday high of $529.15. Healthcare investors are awaiting further updates on production timelines, while simultaneously monitoring macroeconomic data such as the Chinese Manufacturing PMI, which recorded 50.3 on June 30, 2026, due to its indirect impact on the company's global supply chains.